Ongoing Trials
- A multicenter trial assessing the impact of Lp(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis (Lp(a)FRONTIERS CAVS) (NCT05646381)
- Assessing the impact of Lp(a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with CVD (Lp(a)HORIZON) (NCT04023552)
Completed Trials
- Multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the rate of weekly lipoprotein apheresis sessions in patients with hyperlipoproteinemia(a) and established cardiovascular disease in Germany (NCT05305664)
- Phase 2 study of pelacarsen (ISIS 681257; AKCEA-APO(a)-LRx) in participants with hyperlipoproteinemia(a) and cardiovascular disease
